MUMBAI, INDIA and PRINCETON, NJ, September 01, 2026 – Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, together with its subsidiaries and/or affiliated companies, “Sun Pharma”) today joined several pharmaceutical companies at a White House ceremony to announce agreements with the U.S. government aimed at prioritizing access to affordable medicines for millions of American patients.
As part of its agreement, Sun Pharma will extend Most Favored Nation (MFN) pricing to state Medicaid programs. Sun Pharma also commits to MFN pricing for future innovative medicine launches. The agreement recognizes Sun Pharma’s investment in the U.S. market by delaying Section 232 tariffs on innovative pharmaceutical products for over two years. Further terms of the agreements remain confidential. “Our mission is to reach people and touch lives by providing quality medicines across a patient’s entire treatment journey, from consumer health products to generics to innovative medicines,” said Rick Ascroft, North America CEO, Sun Pharma, who represented the company at the White House.
“The United States is a key area of investment and expansion for Sun Pharma across clinical development, sales and marketing, and both API and finished products manufacturing. We are proud to play our part in delivering the medicines that millions of American patients count on every day.” Sun Pharma initially built its U.S. presence on a foundation of high-quality generics followed by an increasing emphasis on innovative and specialty medicines.
The company ranks second by prescriptions in U.S. dermatology and continues to expand across dermatology and immunology, cutaneous oncology, and ophthalmology, complementing a robust consumer health products and generics business. The U.S. is Sun Pharma’s largest market for innovative medicines and a cornerstone of its long-term growth strategy, generating approximately 27% of the company’s global revenue. Commitment to the U.S. market was further underscored earlier this year through Sun Pharma’s definitive agreement to acquire Organon & Co. at an enterprise value of $11.75 billion – a milestone that reflects Sun Pharma’s continued investment in American patients, healthcare providers, and communities. Sun Pharma remains focused on its core mission of expanding access to high-quality, affordable medicines for patients in the U.S. and around the world.
